147 related articles for article (PubMed ID: 23339763)
1. Effectiveness of quenchers to reduce radiolysis of (111)In- or (177)Lu-labelled methionine-containing regulatory peptides. Maintaining radiochemical purity as measured by HPLC.
de Blois E; Chan HS; Konijnenberg M; de Zanger R; Breeman WA
Curr Top Med Chem; 2012; 12(23):2677-85. PubMed ID: 23339763
[TBL] [Abstract][Full Text] [Related]
2. Radiolysis-Associated Decrease in Radiochemical Purity of
Larenkov A; Mitrofanov I; Pavlenko E; Rakhimov M
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838872
[TBL] [Abstract][Full Text] [Related]
3. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate.
Petrik M; Laznickova A; Laznicek M; Zalutsky MR
Anticancer Res; 2007; 27(6B):3941-6. PubMed ID: 18225554
[TBL] [Abstract][Full Text] [Related]
4. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
[TBL] [Abstract][Full Text] [Related]
5. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
Breeman WA; De Jong M; Visser TJ; Erion JL; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):917-20. PubMed ID: 12677301
[TBL] [Abstract][Full Text] [Related]
6. From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial.
Pawlak D; Rangger C; Kolenc Peitl P; Garnuszek P; Maurin M; Ihli L; Kroselj M; Maina T; Maecke H; Erba P; Kremser L; Hubalewska-Dydejczyk A; Mikołajczak R; Decristoforo C
Eur J Pharm Sci; 2016 Mar; 85():1-9. PubMed ID: 26826279
[TBL] [Abstract][Full Text] [Related]
7. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system.
Petrik M; Knetsch PA; Knopp R; Imperato G; Ocak M; von Guggenberg E; Haubner R; Silbernagl R; Decristoforo C
Nucl Med Commun; 2011 Oct; 32(10):887-95. PubMed ID: 21876399
[TBL] [Abstract][Full Text] [Related]
8. The radiometal makes a difference. Synthesis and preliminary characterisation of DOTA-minigastrin analogue complexes with Ga, Lu and Y.
Maurin M; Garnuszek P; Baran P; Pawlak D; Mikołajczak R
Nucl Med Rev Cent East Eur; 2015; 18(2):51-5. PubMed ID: 26315862
[TBL] [Abstract][Full Text] [Related]
9. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
[TBL] [Abstract][Full Text] [Related]
10. Absolute peptide quantification by lutetium labeling and nanoHPLC-ICPMS with isotope dilution analysis.
Rappel C; Schaumlöffel D
Anal Chem; 2009 Jan; 81(1):385-93. PubMed ID: 19117464
[TBL] [Abstract][Full Text] [Related]
11. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes.
Sosabowski JK; Mather SJ
Nat Protoc; 2006; 1(2):972-6. PubMed ID: 17406332
[TBL] [Abstract][Full Text] [Related]
12. Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs.
de Blois E; Chan HS; de Zanger R; Konijnenberg M; Breeman WA
Appl Radiat Isot; 2014 Feb; 85():28-33. PubMed ID: 24365877
[TBL] [Abstract][Full Text] [Related]
13. A systematic study on the utility of CHX-A''-DTPA-NCS and NOTA-NCS as bifunctional chelators for
Pandey U; Gamre N; Lohar SP; Dash A
Appl Radiat Isot; 2017 Sep; 127():1-6. PubMed ID: 28478331
[TBL] [Abstract][Full Text] [Related]
14. Oxidant and Antioxidant Effects of Gentisic Acid in a
Trindade V; Balter H
Curr Radiopharm; 2020; 13(2):107-119. PubMed ID: 31526356
[TBL] [Abstract][Full Text] [Related]
15. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.
Ocak M; Helbok A; von Guggenberg E; Ozsoy Y; Kabasakal L; Kremser L; Decristoforo C
Nucl Med Biol; 2011 Feb; 38(2):171-9. PubMed ID: 21315272
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides.
de Blois E; Sze Chan H; Naidoo C; Prince D; Krenning EP; Breeman WA
Appl Radiat Isot; 2011 Feb; 69(2):308-15. PubMed ID: 21145751
[TBL] [Abstract][Full Text] [Related]
17. Preparation of [In-111]-labeled-DTPA-bombesin conjugates at high specific activity and stability: evaluation of labeling parameters and potential stabilizers.
Pujatti PB; Massicano AV; Mengatti J; de Araújo EB
Appl Radiat Isot; 2012 May; 70(5):856-63. PubMed ID: 22405643
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
19. H4octapa: an acyclic chelator for 111In radiopharmaceuticals.
Price EW; Cawthray JF; Bailey GA; Ferreira CL; Boros E; Adam MJ; Orvig C
J Am Chem Soc; 2012 May; 134(20):8670-83. PubMed ID: 22540281
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM).
Wunderlich G; Schiller E; Bergmann R; Pietzsch HJ
Nucl Med Biol; 2010 Nov; 37(8):861-7. PubMed ID: 21055615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
